Juvenescence Stock

www.juvlabs.comHealthcare / BioTech & PharmaFounded: 2018

Juvenescence is a life sciences biotech company developing therapies to modify aging and increase healthy human longevity.

Register To Buy and Sell Shares

For more details on financing and valuation for Juvenescence, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Juvenescence’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Juvenescence.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Juvenescence’s Stock

Can you buy Juvenescence’s stock?
Juvenescence is not publicly traded on NYSE or NASDAQ in the U.S. To buy Juvenescence’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Juvenescence’s stock?
Yes, you can sell stock of a private company like Juvenescence. Forge can help you sell your Juvenescence stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Juvenescence’s stock price?
Juvenescence is a privately held company and therefore does not have a public stock price. However, you may access Juvenescence’s private market stock price with Forge Data.
What is Juvenescence’s stock ticker symbol?
Juvenescence does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

What Is A Longevity Biotechnology Company?
The longevity biotechnology industry is growing rapidly with increasing academic funding and venture investment. However, a recent research paper emphasizes the importance of defining longevity biotechnology companies based on their mission to target the fundamental mechanisms of aging. The paper also provides specific criteria for a company to be classified as an LBC and offers guidance for investors in this sector.
Tufts professors receive $8 million investment for biotech startup
Morphoceuticals, a biotech company co-founded by Tufts professors Michael Levin and David Kaplan, has received $8 million in seed funding for their innovative regenerative medicine research. The funding will be used to hire staff, purchase equipment, and conduct experiments for FDA approval. Their research is centred around bioelectric controls to induce the regeneration of human tissue, limbs, and organs. The company aims to revolutionize regenerative applications to help millions suffering from various injuries and health conditions.
Finding the Fountain of Youth: Meet the Startups Pioneering Longevity Solutions
The longevity and anti-aging industry is projected to grow from $44 billion in 2020 to $64 billion by 2026. This article explores European startups leading this sector, including Altos Labs, BioSplice Therapeutics, GenFlow Biosciences, and GlycanAge. These companies are developing various solutions, including cellular rejuvenation programming, gene therapy, and biological age testing.
Updated on: May 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.